Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation

NCT06660134 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT06660134
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06660134 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Strict Weight Management and Glycemic Control Based on Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment VS. Conventional Antidiabetic Drugs for Ablation Outcomes in Overweight or Obese Patients with Type 2 Diabetes and Atrial Fibrillation
Lead sponsor
Shanghai Chest Hospital
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2021
Completion date
January 10, 2024
Enrollment
174 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation (af), type 2 diabetes mellitus (t2dm)